Alia Durrani, MD
Retina Specialist · Brentwood, MONPI 1841558822
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Regeneron Healthcare Solutions, Inc. accounts for 61.7% of it on its own, with 19 other manufacturers making up the rest. Among retina specialist clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 111 payments — averaging $473.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$32K
- Ocular Therapeutix, Inc.$5K
- Bausch & Lomb Americas Inc.$4K
- Regeneron$4K
- Genentech USA, Inc.$3K
- Eyepoint US, Inc.$2K
- plus $2K from 14 others
Across 71 payments — averaging $17,468 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$1.2M
- Regeneron$69K
What the payments were for
- Consulting fees$21,41941%
- Speaking & faculty fees$27,50052%
- Food & beverage$3,5677%
- Gifts$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 32 | $32,415 |
| Ocular Therapeutix, Inc. | 6 | $4,695 |
| Bausch & Lomb Americas Inc. | 6 | $4,331 |
| Regeneron | 3 | $4,324 |
| Genentech USA, Inc. | 15 | $3,118 |
| Eyepoint US, Inc. | 2 | $2,018 |
| Astellas Pharma US Inc | 12 | $424 |
| Novartis | 7 | $226 |
| Alimera Sciences, Inc. | 8 | $209 |
| ANI Pharmaceuticals, Inc. | 2 | $154 |
| Harrow Eye, LLC | 2 | $144 |
| Apellis Pharmaceuticals, Inc. | 1 | $132 |
| Carl Zeiss Meditec, Inc. | 3 | $131 |
| AbbVie(2 entities) | 5 | $85 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Biogen | 1 | $18 |
| Gilead | 1 | $17 |
| Alcon | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,522 in reported general payments places this provider in the 90th percentile of 45 retina specialist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 258 | $8,813 |
| ProlensaBromfenac Sodium | 23 | $7,873 |
| Ketorolac Tromethamine | 265 | $4,764 |
| Bromfenac Sodium | 22 | $3,208 |
| MoxifloxacinMoxifloxacin Hcl | 86 | $1,784 |
| Difluprednate | 14 | $1,570 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 126 | $1,541 |
| Loteprednol Etabonate | 11 | $1,475 |
| Brimonidine Tartrate | 62 | $1,453 |
| Mycophenolate Mofetil | 16 | $1,033 |
| Dorzolamide Hcl | 41 | $762 |
| Latanoprost | 46 | $541 |
| ErythromycinErythromycin Base | 30 | $250 |
| Timolol Maleate | 22 | $164 |
| Prednisone | 11 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $27 | $9,34834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 45 retina specialist providers in Missouri.
Other retina specialist in Brentwood
- Kevin BlinderBrentwood$333K
- Sabin DangBrentwood$174K
- Athanasios PapakostasBrentwood$85K
- Barton BlackorbyBrentwood$31K
- Ollya FromalBrentwood$14K
- Nicholas IafeBrentwood$9K
- Dillan PatelBrentwood$5K
- Bradley SmithBrentwood$5K
- William AndersonBrentwood$4K
- Prithvi BomdicaBrentwood$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.